SyntekaBio Q1 2026: Revenue Decline, Continued Losses, New Tech Transfer Deals

Consolidated Q1 2026 revenue: KRW 0.42bn (down 51.6% YoY from KRW 0.87bn)
Consolidated operating loss: KRW 3.51bn (narrowed from KRW 7.29bn YoY)
Consolidated net loss: KRW 3.49bn (narrowed from KRW 7.29bn YoY)
Separate Q1 2026 revenue: KRW 0.41bn (down 53.1% YoY from KRW 0.87bn)
Separate operating loss: KRW 3.36bn (narrowed from KRW 7.29bn YoY)
Debt-to-equity ratio: 54.2% (consolidated); Convertible bonds: KRW 7.57bn; Derivative liabilities: KRW 3.42bn
Cash and cash equivalents: KRW 13.40bn (down from KRW 16.35bn at FY2025 end)
R&D expenses: KRW 1.45bn (357% of revenue)
Accumulated deficit: KRW 97.32bn
Key contracts: Panoros Bio antibody tech transfer (KRW 2.5bn), Kangen autoimmune candidates (KRW 0.45bn), Pragma Biosciences DeepMatcher service ($3.1mn)
No dividends or share buybacks